LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Biotechnology

Healthcare
$40.06 -1.30%

-$0.39 today

Market cap
$1.30B
Beta
0.71
P/E (TTM)
-21.4
EPS (TTM)
-$1.39
52W Low $13.36High $33.47

Volume 0.36M

Average 0.23M

LBRX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

LB Pharmaceuticals Inc Common StockNASDAQ: LBRX

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $3.46M, compared with -$2.89M a year earlier. Trailing-twelve-month accounts payables was $5.43M.

Context

  • Accounts payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $3.46M or moves back toward the trailing-twelve-month quarterly average of $1.36M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.46M+76.3% QoQ
Last fiscal yearDec 2025
-$910K— YoY
LTMMar 2026
$5.43M— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+219.7%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(910K) USD
Year-over-year change
—

Accounts Payables vs competitors

How LBRX compares with its peers on the latest reported figures

  • LBRX's LTM Mar 2026 accounts payables of $5.43M is the 2nd largest of the 10 companies compared; the peer median is $1.08M.
LBRX Competitors Peer median
Accounts Payables for LBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$24.47M +11282.3%—2.1%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$5.43M ———
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$4.34M +345.5%—21.7%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$4M +845.6%——
DNLIDenali Therapeutics Inc.LTM Jun 2026$3.38M +7.9%—93.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$1.98M +327.2%-39.7%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$1.08M -81.9%——
NERVMinerva Neurosciences, Inc.LTM Jun 2026$423.37K —+6.2%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$190K +249.6%——
GHRSGH Research PLCLTM Mar 2026$0 ———
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding LBRX) $1.08M+327.2%-16.7%21.7%

Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.35M)(6.28M)(63.1M)(25.21M)
Depreciation & Amortization2K4K91K321K
Deferred Income Tax0000
Stock-Based Compensation431K295K3.16M0
Change in Working Capital86K(1.31M)3.31M(13.65M)
Accounts Receivables0(154K)114K(268K)
Inventory0000
Accounts Payables000(910K)
Other Working Capital86K(1.16M)3.2M(12.47M)
Other Non-Cash Items11.1M(4.81M)3.49M3.33M
Operating Cash Flow(2.73M)(12.09M)(53.05M)(35.21M)
Capital Expenditures0(25K)(769K)(52K)
Acquisitions (Net)0000
Purchases of Investments0(33.99M)(29.75M)(44.84M)
Sales of Investments123K6M53.75M5M
Other Investing Activities0000
Investing Cash Flow123K(28.01M)23.23M(39.89M)
Debt Repayment25.01M725K00
Common Stock Issued000302.56M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(2.95M)(2.05M)(1.69M)0
Financing Cash Flow22.96M33.68M38.32M302.56M
Effect of Forex Changes000(272K)
Net Change in Cash20.36M(6.43M)8.5M227.2M
Free Cash Flow(2.73M)(12.12M)(53.82M)(35.26M)

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Intrinsic Alpha fair value

Locked

Current Price

$40.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.